Prolonged urticaria with 17-1A antibody.
作者信息
Sizmann N, Korting H C
机构信息
Klinikum Innenstadt, Department of Dermatology, D-80337 Munich, Germany.
出版信息
BMJ. 1998 Dec 12;317(7173):1631. doi: 10.1136/bmj.317.7173.1631.
Abstract
摘要
相似文献
1
Prolonged urticaria with 17-1A antibody.伴有17-1A抗体的慢性荨麻疹
BMJ. 1998 Dec 12;317(7173):1631. doi: 10.1136/bmj.317.7173.1631.
2
Urticarial vasculitis due do infliximab.
J Eur Acad Dermatol Venereol. 2008 Jul;22(7):882-3. doi: 10.1111/j.1468-3083.2007.02480.x. Epub 2008 May 6.
3
Hand eruption after intravenous administration of bevacizumab.静脉注射贝伐单抗后手部皮疹。
J Eur Acad Dermatol Venereol. 2011 Feb;25(2):238-9. doi: 10.1111/j.1468-3083.2010.03708.x. Epub 2010 May 7.
4
[Diagnostic and physiopathological innovations related to chronic urticaria].
Ann Dermatol Venereol. 2010 May;137(5 Suppl 1):24-7. doi: 10.1016/S0151-9638(10)70021-1.
5
Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis.两名系统性发作幼年特发性关节炎患儿因英夫利昔单抗出现延迟性斑丘疹、荨麻疹样皮疹。
Rheumatology (Oxford). 2004 May;43(5):674-5. doi: 10.1093/rheumatology/keh142.
6
Interleukin-3-induced urticaria-like eruption.白细胞介素-3诱导的荨麻疹样皮疹。
J Am Acad Dermatol. 1996 Jun;34(6):1076-8. doi: 10.1016/s0190-9622(96)90291-1.
7
Multiple inflammatory lesions in an oncology patient.
Int J Dermatol. 2016 Dec;55(12):1301-1303. doi: 10.1111/ijd.13144. Epub 2015 Dec 28.
8
Delayed urticaria with oxaliplatin.奥沙利铂所致迟发性荨麻疹
Contact Dermatitis. 2010 Jul;63(1):50-3. doi: 10.1111/j.1600-0536.2010.01738.x.
9
Contact urticaria induced by mexiletine hydrochloride in a patient receiving iontophoresis.在接受离子电渗疗法的患者中，盐酸美西律诱发的接触性荨麻疹。
Br J Dermatol. 1994 Apr;130(4):538-40. doi: 10.1111/j.1365-2133.1994.tb03395.x.
10
Images in clinical medicine. Cetuximab-associated acneiform eruption.临床医学影像。西妥昔单抗相关的痤疮样皮疹。
N Engl J Med. 2005 Nov 10;353(19):e17. doi: 10.1056/NEJMicm050560.
引用本文的文献
1
Simulation and Stability Assessment of Anti-EpCAM Immunotoxin for Cancer Therapy.用于癌症治疗的抗EpCAM免疫毒素的模拟与稳定性评估
Adv Pharm Bull. 2018 Aug;8(3):447-455. doi: 10.15171/apb.2018.052. Epub 2018 Aug 29.
本文引用的文献
1
Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A.接受单克隆抗体17-1A治疗的癌症患者的体液抗独特型和抗抗独特型免疫反应
Cancer Immunol Immunother. 1996 Feb;42(2):81-7. doi: 10.1007/s002620050255.
2
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group.单克隆抗体用于 Dukes' C 期结肠癌切除术后辅助治疗的随机试验。德国癌症援助组织 17-1A 研究小组。
Lancet. 1994 May 14;343(8907):1177-83. doi: 10.1016/s0140-6736(94)92398-1.
3
An overview of adjuvant therapy for colorectal cancer.结直肠癌辅助治疗概述。
Eur J Cancer. 1995 Jul-Aug;31A(7-8):1255-63. doi: 10.1016/0959-8049(95)00258-k.
4
Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.人抗独特型抗体在患者中诱导了针对一种结直肠癌相关抗原的体液免疫和细胞免疫反应。
Proc Natl Acad Sci U S A. 1995 May 23;92(11):4773-7. doi: 10.1073/pnas.92.11.4773.
5
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.人源化小鼠单克隆抗体在人体内的动力学及免疫反应
Proc Natl Acad Sci U S A. 1989 Jun;86(11):4220-4. doi: 10.1073/pnas.86.11.4220.
Zotero 插件